Q4 FY2026 · ended Jun 30, 2026 · Revenue $321.19M, +1.3% YoY · Filed Aug 24, 2026
Bio-Techne Corp (TECH) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $321.2 million and net income of $54.6 million. Free cash flow was $86.9 million. As of Jun 30, 2026 it held $264.7 million in cash and investments and $289.1 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $321.2M | $311.4M | $295.9M | $286.6M | $317.0M |
| Operating income | $74.3M | $75.5M | $54.5M | $47.7M | -$23.9M |
| Net income | $54.6M | $51.0M | $38.0M | $38.2M | -$17.7M |
| Diluted EPS | $0.35 | $0.32 | $0.24 | $0.24 | -$0.11 |
| Operating cash flow | $95.4M | $86.7M | $82.4M | $27.6M | $98.2M |
| Free cash flow | $86.9M | $77.6M | $76.5M | $22.2M | $93.3M |
| Total assets | $2.6B | $2.6B | $2.5B | $2.5B | $2.6B |
| Stockholders' equity | $2.1B | $2.1B | $2.0B | — | — |
| Cash and investments | $264.7M | $209.8M | $172.9M | $145.0M | $162.2M |
| Total debt | $289.1M | $290.3M | $350.9M | $394.5M | $444.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-K/A | Amended annual report | Oct 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-K | Annual report | Aug 24, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
All 1001 Bio-Techne Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.